GURU.Markets stock price, segment price, and overall market index valuation
The company's share price aTyr Pharma Inc.
aTyr Pharma is a biotech company developing drugs based on a new class of proteins. Its stock price represents a venture bet on the success of its scientific platform. The chart reflects the high volatility associated with clinical trial news.
Share prices of companies in the market segment - Pharma immune
aTyr Pharma is a biopharmaceutical company developing a new class of protein therapeutics based on tRNA synthetases for the treatment of immune diseases. We classify it as "Immune Pharmaceuticals." The chart below illustrates the overall dynamics of this cutting-edge segment.
Broad Market Index - GURU.Markets
aTyr Pharma is a biotech company developing drugs based on the novel biology of tRNA synthetases for the treatment of rare immune diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how aTyr shares correlate with sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ATYR - Daily change in the company's share price aTyr Pharma Inc.
For aTyr Pharma, Inc., a biopharmaceutical company, the daily price change is a measure of the high volatility typical of the sector. This metric reflects the market's reaction to drug development news and is critical to the risk assessment formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
aTyr Pharma, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ATYR, which focuses on immune disease treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
aTyr Pharma is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization aTyr Pharma Inc.
For aTyr Pharma, Inc., the year-over-year trend is a story of developing a new class of protein therapeutics. Its 12-month market cap is entirely dependent on clinical trial data for its lead drug for the treatment of pulmonary sarcoidosis. Success in this area could confirm the potential of its unique scientific platform.
Annual dynamics of market capitalization of the market segment - Pharma immune
aTyr Pharma, Inc. is a clinical-stage biotech company developing a new class of drugs for the treatment of inflammatory diseases. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this complex area of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
aTyr Pharma is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization aTyr Pharma Inc.
aTyr Pharma is a clinical-stage biotech focused on immunology. Its monthly market cap is a barometer of its research. Any news about the clinical trial results of its lead drug, efzofitimod, triggers an immediate and strong investor reaction, as reflected in the chart.
Monthly dynamics of market capitalization of the market segment - Pharma immune
aTyr Pharma is a biotech company developing drugs based on the novel biology of tRNA synthetases for the treatment of interstitial lung diseases and other immune disorders. The graph below illustrates the dynamics of the biotech sector, where the discovery of new biological mechanisms can lead to the creation of new classes of drugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
aTyr Pharma is a biotech company exploring new areas of biology to create innovative drugs. Its shares move in sync with news about clinical trials. The success or failure of a single study can dramatically change the company's value, making its dynamics independent of the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization aTyr Pharma Inc.
aTyr Pharma, a biotech company developing drugs based on novel biology, exhibits high volatility. Weekly stock performance depends on data from clinical trials in the field of immunology, where any news can lead to sharp movements, reflecting the risks and potential of scientific discoveries.
Weekly dynamics of market capitalization of the market segment - Pharma immune
aTyr Pharma is researching a new class of protein therapeutics. In immunology, breakthroughs can lead to explosive growth. This chart offers a chance to see whether aTyr's share price movements are a unique reaction to research data or reflect the overall sentiment in its innovative pharmaceutical sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
aTyr Pharma is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that aTyr's performance is largely uncorrelated with the market, moving based on its own unique news rather than general trends.
Market capitalization of the company, segment and market as a whole
ATYR - Market capitalization of the company aTyr Pharma Inc.
The aTyr Pharma chart is a financial map of immunology research. This biotech company's market cap reflects the hopes for its drugs to treat rare inflammatory lung diseases. Its dynamics are a barometer of how investors view the company's scientific platform and its progress in clinical development.
ATYR - Share of the company's market capitalization aTyr Pharma Inc. within the market segment - Pharma immune
aTyr Pharma's market share in the immunology sector reflects its research focus. The company operates at the cutting edge of science, developing a new class of protein therapeutics. Its market share reflects investor assessments of the potential of its unique scientific platform, not current sales.
Market capitalization of the market segment - Pharma immune
aTyr Pharma is researching a new class of protein modulators for the treatment of immune diseases. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect investors' faith in new scientific approaches and their willingness to finance long-term, risky developments.
Market capitalization of all companies included in a broad market index - GURU.Markets
aTyr Pharma develops new drugs based on natural proteins for the treatment of immunological diseases. Its market capitalization reflects the potential of its scientific platform. The chart below shows the economic weight of biotech companies using innovative approaches in immunology.
Book value capitalization of the company, segment and market as a whole
ATYR - Book value capitalization of the company aTyr Pharma Inc.
For aTyr Pharma, a biopharmaceutical company, book value is its R&D capital. The chart below shows financial resources, not production capacity. Its dynamics reflect how the company manages its funds for research in immunology and rare diseases.
ATYR - Share of the company's book capitalization aTyr Pharma Inc. within the market segment - Pharma immune
aTyr Pharma is a biotech company exploring a new area of biology to create immunomodulatory drugs. Its main asset is its scientific platform. The share of tangible assets will be low, reflecting its focus on R&D, where laboratories, rather than manufacturing facilities, are the primary facilities.
Market segment balance sheet capitalization - Pharma immune
aTyr Pharma is a clinical-stage biotech company. Its value is created not in factories, but in laboratories. This is a "light" model based on intellectual capital. The chart below shows how much the biopharmaceutical industry as a whole relies on tangible assets versus intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
aTyr Pharma's assets are capital invested in studying the new biology of tRNA synthetases for the development of immunomodulatory drugs. The book value reflects the investment in this cutting-edge scientific platform, which could unlock a new class of drugs for the treatment of inflammatory and immune diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - aTyr Pharma Inc.
aTyr Pharma is a biotech company exploring a new area of biology related to tRNA synthetases. Its balance sheet is cash-based, and its market capitalization reflects pure faith in its scientific platform. This chart reflects how the market perceives the risks and potential of a company operating at the cutting edge of fundamental science.
Market to book capitalization ratio in a market segment - Pharma immune
aTyr Pharma is a biotech company working in the field of immunology. Its core assets are not its laboratories, but its scientific platform and pipeline of research drugs. The chart shows the market premium the company is valuing in anticipation of successful clinical trials and the launch of new drugs.
Market to book capitalization ratio for the market as a whole
aTyr Pharma is a biotech company exploring a new area of biology to develop immunomodulatory drugs. The chart shows how the market values cutting-edge science. aTyr's market capitalization is based not on its current assets, but on the potential of its scientific platform to create a whole new class of drugs, which shapes investor expectations.
Debts of the company, segment and market as a whole
ATYR - Company debts aTyr Pharma Inc.
aTyr Pharma is a biotechnology company exploring a new area of biology to develop immunomodulatory drugs. Its leverage during clinical development allows it to finance expensive research without excessively diluting its equity. This chart shows how the company raises resources to test its scientific hypotheses.
Market segment debts - Pharma immune
aTyr Pharma is a biopharmaceutical company developing drugs based on the novel biology of tRNA synthetases for the treatment of immune diseases. This is a cutting-edge scientific field that requires long-term investment. The chart shows common financial indicators for the pharmaceutical sector, which can be used to evaluate aTyr's strategy for funding its unique and risky research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio aTyr Pharma Inc.
aTyr Pharma develops innovative drugs that target the immune system. Biotech development is a marathon that requires constant funding. This chart shows the company's reliance on borrowed funds for research. This gives investors an understanding of its financial risks and the "margin of safety" it has until results are achieved.
Market segment debt to market segment book capitalization - Pharma immune
Developing drugs based on proteins synthesized by tRNA, like those developed by aTyr Pharma, is at the cutting edge of biotechnology. This chart shows how the sector as a whole funds its research. It allows one to assess how the company's unique scientific platform and financial model differentiate it from other players in the field of immunology and inflammatory diseases.
Debt to book value of all companies in the market
aTyr Pharma operates in the cutting-edge field of immunology, where research takes years and hundreds of millions of dollars to generate revenue. For these companies, debt is a bridge to the future. This chart demonstrates how much leverage they have compared to the overall market, and how investors assess their risk.
P/E of the company, segment and market as a whole
P/E - aTyr Pharma Inc.
This metric for aTyr Pharma, Inc., a biopharmaceutical company researching a new class of protein therapeutics, reflects future expectations. For a company in the clinical development stage, its value is determined not by current revenues, but by investors' faith in its scientific platform. The graph shows an assessment of its innovative potential.
P/E of the market segment - Pharma immune
This metric represents the average valuation for the biotech sector in which aTyr Pharma operates. In this industry, which is full of research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark.
P/E of the market as a whole
aTyr Pharma develops new drugs based on rare proteins for the treatment of immune diseases. It is a research company whose value is tied to the potential of its scientific platform. This chart shows the overall risk appetite of investors. It helps us understand whether aTyr Pharma is supported by the general interest in biotech or whether its valuation is moving independently, in sync with scientific data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company aTyr Pharma Inc.
aTyr Pharma is exploring a new area of biology related to tRNA synthetases to develop innovative treatments for immune diseases, particularly pulmonary sarcoidosis. The company's future depends on the results of clinical trials. This timeline reflects investor expectations regarding the potential of its unique scientific approach and the commercial prospects of its lead drug candidate.
%20P%2FE%20aTyr%20Pharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-aTyr-Pharma-Inc.&v=1772665008180 "Chart of the company's future (projected) P/E aTyr Pharma Inc.")
Future (projected) P/E of the market segment - Pharma immune
aTyr Pharma is a biotech company exploring a new, previously unknown area of biology—tRNA synthetase proteins—to create innovative drugs. The company operates at the forefront of science. This chart reflects expectations for the biotech sector, providing context for how the market views this bold and high-risk scientific approach.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772665008198 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
aTyr Pharma is a biotech company exploring a new area of biology related to tRNA synthetases for the treatment of immune diseases. Their work requires long-term investment in science. This graph of overall expectations shows investor sentiment toward risky but potentially breakthrough projects. Market optimism facilitates raising capital to fund their unique research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772665008209 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit aTyr Pharma Inc.
aTyr Pharma is a biotechnology company exploring a new area of biology related to tRNA synthetases for the treatment of immune diseases. This chart shows the cost of cutting-edge research. Profitability is a long-term goal for the company, and current financial metrics reflect investments in clinical programs and platform development.
Profit of companies in the market segment - Pharma immune
Santech Holdings is an internet technology company. Its profitability depends on its ability to create and monetize a popular digital product or service. This chart reflects the highly competitive internet business environment, where network effects and innovation can lead to rapid growth but also to rapid decline, making profitability volatile.
Overall market profit
aTyr Pharma is a biotech company exploring a new area of biology to create immunomodulatory drugs. Currently in clinical development, its trajectory is entirely dependent on scientific discoveries and research data. It is an example of a business whose potential value is formed in the laboratory, separate from the general economic trends reflected here.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company aTyr Pharma Inc.
aTyr Pharma is a biotech company developing drugs based on novel tRNA synthetase biology for the treatment of rare immune diseases. Its revenue forecast is dependent on the success of clinical trials. This chart reflects analysts' long-term expectations for aTyr's scientific approach and its ability to create a new class of drugs for the treatment of pulmonary and inflammatory diseases.
%20profit%20of%20the%20company%20aTyr%20Pharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-aTyr-Pharma-Inc.&v=1772665008289 "Graph of future (projected) profit of the company aTyr Pharma Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
aTyr Pharma is exploring a new area of biology related to protein synthetases to develop drugs for fibrotic and inflammatory diseases. The company operates at the forefront of science. This chart shows profitability forecasts for the biotech sector. It reflects the overall investor confidence in the potential of discovering entirely new classes of therapeutics.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772665008293 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
aTyr Pharma operates in the field of immunology, developing drugs based on new discoveries in protein biology. It's a knowledge-intensive business that requires long-term investment. The presented graph of corporate earnings expectations reflects the overall investment climate. During periods of optimism, companies like aTyr find it easier to attract capital for breakthrough research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772665008321 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - aTyr Pharma Inc.
aTyr Pharma is a biotech company exploring a new area of biology related to tRNA synthetases to create immunomodulatory drugs. Its revenue is currently negligible. The chart reflects investor sentiment not on current sales, but on the potential of its scientific platform to develop a new class of drugs for the treatment of inflammatory and immune diseases.
P/S market segment - Pharma immune
aTyr Pharma, Inc. is a clinical-stage biotherapeutics company developing novel therapies based on immune-modulating proteins for the treatment of pulmonary and inflammatory diseases. This chart shows the average valuation in the sector, allowing investors to understand how the market views the potential of aTyr's scientific platform.
P/S of the market as a whole
aTyr Pharma is exploring a new area of biology related to tRNA synthetases to develop drugs for immune diseases. The company is in early-stage clinical trials. This chart, reflecting the average real revenue estimate for the market, clearly highlights how investing in breakthrough science differs from investing in companies with existing sales.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company aTyr Pharma Inc.
aTyr Pharma develops innovative drugs based on the novel biology of transport RNA synthetases for the treatment of immune diseases. This chart reflects investor expectations for the future success of its clinical programs. The valuation is based on potential future revenues from drugs targeting rare pulmonary and inflammatory diseases.
%20P%2FS%20aTyr%20Pharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-aTyr-Pharma-Inc.&v=1772665008420 "The graph of the company's future (projected) P/S aTyr Pharma Inc.")
Future (projected) P/S of the market segment - Pharma immune
aTyr Pharma is exploring a new area of biology related to tRNA synthetases to develop innovative immunomodulatory drugs for the treatment of pulmonary and inflammatory diseases. This chart shows how the market assesses aTyr's future sales potential compared to other biotech companies, reflecting expectations for its innovative scientific approach.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772665008440 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
The overall economic revenue forecast hinges on the search for new approaches to treating complex diseases. aTyr Pharma is exploring a new area of protein biology to develop immunomodulatory drugs. Their innovative approach, although still in its early stages, reflects investors' belief that fundamental science is the source of future therapeutic breakthroughs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772665008481 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales aTyr Pharma Inc.
aTyr Pharma is a clinical-stage biopharmaceutical company exploring a new area of biology: signaling proteins. Currently, its revenue is generated primarily from collaboration agreements and licensing fees, rather than product sales. This chart reflects progress in research and partnerships, which are the foundation for future growth.
Sales of companies in the market segment - Pharma immune
aTyr Pharma is exploring a new area of biology based on a previously unknown class of proteins to develop drugs for immune diseases, specifically pulmonary sarcoidosis. This chart shows the overall revenue in the immunology pharmaceutical sector and the size of the market the company is targeting with its unique approach to treating inflammatory conditions.
Overall market sales
aTyr Pharma is a biotherapeutic company exploring a new area of biology related to protein synthetases to develop immunomodulatory drugs. Currently in clinical trials, its prospects depend on scientific discoveries and funding. This general economic climate chart reflects investor appetite for fundamental biotech research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company aTyr Pharma Inc.
aTyr Pharma is a biotech company developing a new class of proteins for the treatment of pulmonary and immune diseases. Its success depends on the results of clinical trials. The chart shows analysts' speculative revenue forecasts, which are a bet on the company proving the effectiveness of its innovative approach and bringing the drug to market.
%20sales%20of%20the%20company%20aTyr%20Pharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-aTyr-Pharma-Inc.&v=1772665008673 "Schedule of future (projected) sales of the company aTyr Pharma Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
aTyr Pharma is a biotechnology company exploring a new area of biology related to tRNA synthetases to create immunomodulatory drugs. The company's success depends on clinical data. This chart displays projected sales for the entire immunological pharmaceutical segment, demonstrating overall growth expectations for this cutting-edge field of medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772665008734 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
aTyr Pharma is a biotherapeutic company developing drugs based on novel tRNA synthetase biology for the treatment of immune diseases. Its future depends on the success of its clinical programs. This overall economic activity schedule impacts the availability of venture capital and partnerships with major pharma, which are necessary to fund aTyr's costly research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772665008755 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality aTyr Pharma Inc.
aTyr Pharma is a biotechnology company developing a new class of protein therapeutics. This indicator reflects its scientific activity in financial terms. It shows the amount of investment in research and clinical trials, which are a necessary step on the path to developing a commercially successful drug.
Market segment marginality - Pharma immune
aTyr Pharma is a biopharmaceutical company developing drugs based on the novel biology of tRNA synthetases for the treatment of immune diseases. Profitability is a future goal. This metric reflects the company's operational structure and level of investment in its unique scientific platform compared to other immunology companies.
Market marginality as a whole
aTyr Pharma is a biotherapeutics company developing novel protein-based therapies targeting the immune system to combat rare lung diseases and cancer. Their success depends entirely on the results of clinical trials. This overall profitability curve is important to them only in terms of the overall investment climate in the risky biotech sector.
Employees in the company, segment and market as a whole
Number of employees in the company aTyr Pharma Inc.
aTyr Pharma is a biotechnology company focused on immunology. While in the clinical stage, its staff consists primarily of highly qualified scientists. This chart illustrates how the company is expanding its team to conduct increasingly complex and large-scale clinical trials of its therapeutic candidates.
Share of the company's employees aTyr Pharma Inc. within the market segment - Pharma immune
aTyr Pharma is exploring a new area of biology related to synthetase proteins to create immunomodulatory drugs. This graph shows the concentration of exceptional scientists in this cutting-edge field. The company's share of such talent reflects its role as a pioneer in the development of an entirely new class of drugs.
Number of employees in the market segment - Pharma immune
aTyr Pharma, Inc. is a biotechnology company exploring a new area of biology related to tRNA synthetases to develop immunomodulatory drugs. This chart shows overall employment in the immunology research sector. It illustrates how actively the scientific community is seeking new approaches to treating diseases related to the immune system.
Number of employees in the market as a whole
aTyr Pharma is researching a new area of biology related to protein synthetases for the development of immunomodulatory drugs. This is at the cutting edge of science, requiring unique competencies. This graph, illustrating the overall labor market, also includes breakthrough biotech companies, where staff growth signifies advances in the understanding and treatment of complex diseases.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company aTyr Pharma Inc. (ATYR)
aTyr Pharma is a biotech company exploring a new area of biology to develop immunomodulatory drugs. This chart reflects the market's high valuation of the team's scientific potential. At such companies, value is created not by the number of employees, but by their unique knowledge and discoveries, which leads to high market capitalization per team member.
%20of%20the%20company%20aTyr%20Pharma%20Inc.%20(ATYR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-aTyr-Pharma-Inc.-ATYR&v=1772665009082 "Chart of market capitalization per employee (in thousands of dollars) of the company aTyr Pharma Inc. (ATYR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
aTyr Pharma is a biotech company exploring a new area of biology to develop immunomodulatory drugs. Their value is almost entirely derived from intellectual capital. This chart shows how highly the market values their scientific platform and the potential of future drugs. The higher the value, the greater the investors' faith in the uniqueness of their approach.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772665009231 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
aTyr Pharma, Inc. is a biopharmaceutical company exploring a new area of biology related to tRNA synthetases for the treatment of immune diseases. Its valuation is based on the scientific potential of its platform. The high valuation per employee illustrates how the market values breakthrough research that has the potential to unlock entirely new approaches to treating diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772665009249 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company aTyr Pharma Inc. (ATYR)
aTyr Pharma is a clinical-stage biotech company developing drugs based on the novel biology of tRNA synthetases for the treatment of immune diseases. This is pure R&D. This metric demonstrates their capital burn rate: it shows the net loss per scientist working on discoveries in this new field.
%20Chart%20aTyr%20Pharma%20Inc.%20(ATYR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-aTyr-Pharma-Inc.-ATYR&v=1772665009269 "Company Profit Per Employee (in thousands of dollars) Chart aTyr Pharma Inc. (ATYR)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
aTyr Pharma is a clinical-stage company exploring a new area of biology to develop immunomodulatory drugs. As with most biotech companies, this timeline represents a long-term goal. Currently, profitability per employee is negative. Success will mean their scientific platform is capable of generating intellectual property with enormous value.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772665009292 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
aTyr Pharma (ATYR) is a biopharmaceutical company exploring a new area of biology—proteins associated with tRNA synthetases—for the treatment of immune diseases. This is fundamental science. This chart illustrates the economics of R&D: the high cost of maintaining an elite scientific team in anticipation of commercial revenue that is still lacking.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772665009326 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee aTyr Pharma Inc. (ATYR)
For aTyr Pharma, a biotech company focused on immunology, this graph reflects the performance of its research platform. As drug candidates progress through the clinical stages, revenue per employee will depend on successful partnerships and future commercialization.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-aTyr-Pharma-Inc.-ATYR&v=1772665009354 "Sales chart per company employee aTyr Pharma Inc. (ATYR)")
Sales per employee in the market segment - Pharma immune
aTyr Pharma is a biopharmaceutical company developing drugs based on the novel biology of tRNA synthetases for the treatment of immune diseases. This is a knowledge-intensive R&D company. This metric reflects the average revenue per employee for the segment. It allows us to assess how productive aTyr's R&D team is in advancing its developments compared to other biotech companies in the immunology sector.
Sales per employee for the market as a whole
aTyr Pharma (ATYR) is a clinical-stage biopharmaceutical company exploring new avenues in immunology. Like other R&D companies, its staff consists of scientists. This metric is pending for aTyr. It will only begin to grow if clinical trials are successful and either partner payments are received or marketing approval is granted, which will be a key milestone for investors.
Short shares by company, segment and market as a whole
Shares shorted by company aTyr Pharma Inc. (ATYR)
aTyr Pharma is a biotech company exploring the novel field of tRNA synthetase biology for the treatment of inflammatory diseases. This is cutting-edge, yet largely unproven, science. This chart shows how many investors are betting that this complex scientific platform will fail to translate into effective and safe drugs, leading to clinical failure.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-aTyr-Pharma-Inc.-ATYR&v=1772665009425 "Short Shares Chart for the Company aTyr Pharma Inc. (ATYR)")
Shares shorted by market segment - Pharma immune
aTyr Pharma (ATYR) is a biopharmaceutical company exploring a new area of biology (tRNA synthetases) to develop drugs in the fields of immunology and inflammation. This chart summarizes the bearish bets on the immunology biotech sector. It shows the overall market pessimism regarding the success of clinical trials of fundamentally new, unproven biological targets.
Shares shorted by the overall market
aTyr Pharma (ATYR) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing ATYR will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator aTyr Pharma Inc. (ATYR)
aTyr Pharma is a biotech company working on rare immune diseases (such as pulmonary sarcoidosis). This is a high-risk bet on their R&D platform. This chart measures the extremes of speculative sentiment. It shows when the stock is "overbought" on positive trial data or "oversold" on news of delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-aTyr-Pharma-Inc.-ATYR&v=1772665009518 "RSI 14 indicator chart for the company's stock aTyr Pharma Inc. (ATYR)")
RSI 14 Market Segment - Pharma immune
aTyr Pharma (ATYR) is a biotech company that researches tRNA synthetases. They are searching for new signaling molecules to treat immune diseases (e.g., lung diseases). The Pharma-immune (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is ATYR's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
For aTyr Pharma (ATYR), a biotech company, this chart is the pulse of investors. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to invest generously in risky but breakthrough research. During periods of panic, risk appetite vanishes, and aTyr could face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ATYR (aTyr Pharma Inc.)
aTyr Pharma is a biotech company developing drugs based on novel biology (tRNA synthetase) for the treatment of pulmonary and immune diseases. This chart shows the average target price. Analysts' forecasts are based on clinical data for their lead candidate (efzofitimod) and the platform's potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ATYR-aTyr-Pharma-Inc.&v=1772665009644 "A chart showing analyst consensus forecasts for the expected stock price. ATYR (aTyr Pharma Inc.)")
The difference between the consensus estimate and the actual stock price ATYR (aTyr Pharma Inc.)
aTyr Pharma is a biotech company exploring a new area of biology (tRNA synthetases) to develop drugs against inflammatory and immune diseases. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in the clinical success of this unique scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ATYR-aTyr-Pharma-Inc.&v=1772665009661 "A chart showing the difference between the consensus forecast and the actual stock price. ATYR (aTyr Pharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
aTyr Pharma is a biotech company developing transfer RNA (tRNA)-based drugs for the treatment of rare immune diseases (pulmonary sarcoidosis). This chart reflects general expectations for the immune pharma sector, demonstrating whether experts believe in this new, complex R&D platform.
Analysts' consensus forecast for the overall market share price
aTyr Pharma (ATYR) is a clinical-stage biopharmaceutical company developing a new class of drugs based on tRNA synthetases for the treatment of rare inflammatory diseases (e.g., lung diseases). This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough but high-risk scientific R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index aTyr Pharma Inc.
aTyr Pharma is a clinical-stage biotech company focused on immunology. They are developing drugs (based on a novel tRNA synthetase) for the treatment of rare inflammatory diseases, primarily pulmonary diseases (sarcoidosis). This chart is a pure indicator of confidence in their R&D. It does not reflect revenue, but rather a speculative estimate of their scientific progress and clinical trial data.
AKIMA Market Segment Index - Pharma immune
aTyr Pharma is a biotech company developing drugs based on a new class of proteins (tRNA synthetases) for the treatment of interstitial lung diseases (ILD). This chart shows the average index for the immunopharmaceutical sector. It helps investors assess how aTyr's scientific approach compares to the industry average.
The AKIM Index for the overall market
aTyr Pharma is a biotech company using tRNA synthetase biology to create drugs for rare lung diseases (sarcoidosis). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific platform compares to the overall economic trends affecting the biotech sector.
